The FDA approved the first mRNA flu vaccine in the United States for people aged 50 and older
The FDA approved Moderna’s mRNA seasonal flu vaccine, mFLUSIVA, for people aged 50 and older in the US. Moderna said it is expected to be available in 2026 to 2027. In a trial for ages 50 to 64, it showed 27% fewer confirmed flu cases versus the standard vaccine, with similar safety but more mostly mild side effects. Moderna will collect data to compare with the current high-dose option for ages 65+.
How this was made
The 30-second read
Why it matters
Regulatory approval for ages 50+ is a concrete commercialization step, while the 65+ comparison remains dependent on additional data collection and FDA review.
Market read
This is a first FDA approval for an mRNA flu vaccine in the US for ages 50+, with trial efficacy details and a stated plan for further FDA determination for the 65+ group.
What to watch
The article notes more reported side effects (though mostly mild and short), which could influence uptake, payer decisions, and physician preference versus existing high-dose options.
Background
The FDA previously indicated it would not review Moderna’s application, then reversed after Moderna promised an additional post-marketing study.
Ticker impact
FDA approved Moderna’s seasonal mRNA flu vaccine (mFLUSIVA) for ages 50+ for the 2026-2027 season, with trial efficacy and next-step FDA review details.
Near-term positive bias from regulatory approval, with additional upside or downside contingent on winter data versus the current high-dose vaccine.
The article is a first FDA approval with quantified trial results (27% fewer confirmed cases) and a stated plan to submit additional comparative data for the 65+ group, creating both immediate and follow-on catalysts.
Market effects
Supports the mRNA vaccine platform narrative and may influence investor sentiment toward other mRNA vaccine developers and flu vaccine competitors.
Primarily US regulatory and commercial implications for the US flu vaccine market.
Could strengthen global confidence in mRNA flu vaccine approaches, potentially affecting international adoption discussions.
Counterpoint
The 65+ indication is not fully settled; the need for additional winter comparative data could limit how much of the addressable market is immediately de-risked.
Key entities
- companyModerna
Received FDA approval for its seasonal mRNA flu vaccine mFLUSIVA for people aged 50 and older.
- regulatorU.S. Food and Drug Administration (FDA)
Approved mFLUSIVA for the 2026-2027 respiratory disease season for ages 50+.
- productmFLUSIVA
Moderna’s seasonal mRNA flu vaccine; trial showed 27% fewer confirmed flu cases in ages 50-64 vs standard vaccine.
- government agencyU.S. Department of Health and Human Services (HHS)
Canceled at least $500 million in federal funding for mRNA vaccine development earlier, per the article.
